Molecular Cytogenetics enables the analysis of chromosomal changes over a broad range of focus, from whole genome composition or organization to specific gene copy number or location. It provides a comprehensive genomic context for global or targeted cell biology studies. In contrast to most other approaches, it enables a cell-by-cell survey of chromosomal content, revealing heterogeneity and possible associations within that heterogeneity. Thus cytogenetic analysis remains a simple and efficient first step towards identifying novel areas of genomic change. The Molecular Cytogenetics Core provides MSKCC investigators with effective chromosome-based analyses for human or research animal cells. It processes samples from primary cells, cell lines, or archival tissue, performs chromosome analysis on research samples, using conventional Cytogenetics (chromosome banding and karyotyping) and molecular Cytogenetics procedures based on fluorescence in situ hybridization (FISH), including Spectral Karyotyping (SKY). The Core staff works with investigators to design the most appropriate and efficient analysis for their needs and produces customized probes for specific projects. The Core has assembled a broad range of molecular Cytogenetics resources for human and mouse analysis, including plasmid and BAG clone stocks, as well as chromosome paints. Chromosome analysis is an integral part of research focusing on genomic instability. The Core's experience in karyotyping and chromosome identification provides valuable support to investigators attempting to understand the basis of chromosomal instability in cancer. In addition to specific research applications, the Core also provides an essential function in maintaining Good Laboratory Practice for MSKCC research projects that use cultured cell lines. Karyotype analysis provides basic confirmation and documentation of cell line identity, and is used to monitor chromosomal integrity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-46
Application #
8243719
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-01-01
Budget End
2011-12-31
Support Year
46
Fiscal Year
2011
Total Cost
$203,093
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Munir, Annum; Abdullahu, Leonora; Damha, Masad J et al. (2018) Two-step mechanism and step-arrest mutants of Runella slithyformis NAD+-dependent tRNA 2'-phosphotransferase Tpt1. RNA 24:1144-1157
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Lau, Colleen M; Adams, Nicholas M; Geary, Clair D et al. (2018) Epigenetic control of innate and adaptive immune memory. Nat Immunol 19:963-972
Li, Ruxin; Xiao, Di; Yang, Jing et al. (2018) Identification and Characterization of Clostridium difficile Sequence Type 37 Genotype by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J Clin Microbiol 56:
Zhang, Jennifer Q; Zeng, Shan; Vitiello, Gerardo A et al. (2018) Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6:434-447
Banerjee, Smita C; D'Agostino, Thomas A; Gordon, Mallorie L et al. (2018) ""It's Not JUST Skin Cancer"": Understanding Their Cancer Experience From Melanoma Survivor Narratives Shared Online. Health Commun 33:188-201
Qu, Yang; Emoto, Katsura; Eguchi, Takashi et al. (2018) Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol :
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Chisholm, Julia C; Suvada, Jozef; Dunkel, Ira J et al. (2018) BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer 65:e26947
Niethammer, Philipp (2018) Wound redox gradients revisited. Semin Cell Dev Biol 80:13-16

Showing the most recent 10 out of 8799 publications